Snyder Capital Management L P Has $199.29 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Snyder Capital Management L P grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,168,453 shares of the biopharmaceutical company's stock after purchasing an additional 105,086 shares during the period. Halozyme Therapeutics makes up approximately 4.2% of Snyder Capital Management L P's holdings, making the stock its 4th largest position. Snyder Capital Management L P owned approximately 3.28% of Halozyme Therapeutics worth $199,294,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 197 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock valued at $1,688,000 after acquiring an additional 200 shares in the last quarter. CreativeOne Wealth LLC raised its holdings in Halozyme Therapeutics by 1.6% in the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after acquiring an additional 294 shares during the last quarter. State of New Jersey Common Pension Fund D increased its holdings in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock worth $2,279,000 after purchasing an additional 302 shares in the last quarter. Finally, Parkside Financial Bank & Trust raised its position in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the sale, the director now directly owns 28,611 shares of the company's stock, valued at $1,727,246.07. The trade was a 13.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,697 shares of company stock valued at $1,558,052 in the last 90 days. Company insiders own 2.40% of the company's stock.

Analyst Upgrades and Downgrades

HALO has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Friday. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. JPMorgan Chase & Co. upped their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, Benchmark reaffirmed a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $62.89.

Halozyme Therapeutics Trading Up 0.4 %

NASDAQ HALO traded up $0.25 during trading on Tuesday, hitting $60.82. The stock had a trading volume of 1,147,821 shares, compared to its average volume of 1,435,482. Halozyme Therapeutics, Inc. has a one year low of $37.97 and a one year high of $66.00. The stock has a 50 day simple moving average of $60.56 and a 200 day simple moving average of $55.20. The stock has a market capitalization of $7.51 billion, a price-to-earnings ratio of 17.73, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.